Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBITDA: 2011-2025

Historic EBITDA for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $36.2 million.

  • Ani Pharmaceuticals' EBITDA rose 276.62% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 515.57%. This contributed to the annual value of $8.0 million for FY2024, which is 85.34% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EBITDA of $36.2 million as of Q3 2025, which was up 160.87% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EBITDA registered a high of $36.2 million during Q3 2025, and its lowest value of -$23.7 million during Q4 2021.
  • For the 3-year period, Ani Pharmaceuticals' EBITDA averaged around $11.3 million, with its median value being $12.4 million (2023).
  • Per our database at Business Quant, Ani Pharmaceuticals' EBITDA plummeted by 1,554.51% in 2021 and then surged by 459.32% in 2023.
  • Ani Pharmaceuticals' EBITDA (Quarterly) stood at -$23.7 million in 2021, then soared by 107.67% to $1.8 million in 2022, then spiked by 269.56% to $6.7 million in 2023, then slumped by 165.09% to -$4.4 million in 2024, then soared by 276.62% to $36.2 million in 2025.
  • Its EBITDA stands at $36.2 million for Q3 2025, versus $13.9 million for Q2 2025 and $26.2 million for Q1 2025.